High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants

Vaccine

Volumn 31, Issue 1, 2012, Pages 159-164

  Chen, Xinyuan ^a   Pravetoni, Marco ^b,c   Bhayana, Brijesh ^a   Pentel, Paul R ^b,c   Wu, Mei X ^a,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Addiction; Adjuvant; Immunogenicity; Immunotherapy; Intradermal delivery; Nicotine vaccine

Indexed keywords

NICOTINE VACCINE; PHOSPHORYL LIPID A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CPG ISLAND; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN IRRITATION; SKIN MANIFESTATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; NICOTINE; TOBACCO USE DISORDER; VACCINES;

EID: 84870506539     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.069     Document Type: Article

References (32)

1. Hays J.T., Ebbert J.O. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2010, 70(18):2357-2372.
2. Cerny E.H., Cerny T. Vaccines against nicotine. Hum Vaccine 2009, 5(4):200-205.
3. Maurer P., Bachmann M.F. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs 2007, 16(11):1775-1783.
4. Cornuz J., Zwahlen S., Jungi W.F., Osterwalder J., Klingler K., van Melle G., et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 2008, 3(6):e2547.
5. Hatsukami D.K., Jorenby D.E., Gonzales D., Rigotti N.A., Glover E.D., Oncken C.A., et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011, 89(3):392-399.
6. Hieda Y., Keyler D.E., Vandevoort J.T., Kane J.K., Ross C.A., Raphael D.E., et al. Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 1997, 283(3):1076-1081.
7. Fahim R.E., Kessler P.D., Fuller S.A., Kalnik M.W. Nicotine vaccines CNS. Neurol Disord Drug Targets 2011, 10(8):905-915.
8. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351(22):2295-2301.
9. Van Damme P., Arnou R., Kafeja F., Fiquet A., Richard P., Thomas S., et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010, 10:134.
10. Mikszta J.A., Dekker J.P., Harvey N.G., Dean C.H., Brittingham J.M., Huang J., et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect Immun 2006, 74(12):6806-6810.
11. Redfield R.R., Innis B.L., Scott R.M., Cannon H.G., Bancroft W.H. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 1985, 254(22):3203-3206.
12. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004, 351(22):2286-2294.
13. Chen X., Wu M.X. Laser vaccine adjuvant for cutaneous immunization. Expert Rev Vaccines 2011, 10(10):1397-1403.
14. Schijns V.E., Lavelle E.C. Trends in vaccine adjuvants. Expert Rev Vaccines 2011, 10(4):539-550.
15. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183(10):6186-6197.
16. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24(33-34):5937-5949.
17. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011, 10(4):499-511.
18. Adams S., O'Neill D.W., Nonaka D., Hardin E., Chiriboga L., Siu K., et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008, 181(1):776-784.
19. Herrera S., Fernandez O.L., Vera O., Cárdenas W., Ramírez O., Palacios R., et al. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am J Trop Med Hyg 2011, 84(Suppl. 2):12-20.
20. Chen X., Kim P., Farinelli B., Doukas A., Yun S.H., Gelfand J.A., et al. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS ONE 2010, 5(10):e13776.
21. Raman V.S., Bhatia A., Picone A., Whittle J., Bailor H.R., O'Donnell J., et al. Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol 2010, 185(3):1701-1710.
22. Theiner G., Rossner S., Dalpke A., Bode K., Berger T., Gessner A., et al. TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells. Mol Immunol 2008, 45(1):244-252.
23. LeSage M.G., Keyler D.E., Pentel P.R. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J 2006, 8(1):E65-E75.
24. Roiko S.A., Harris A.C., Keyler D.E., LeSage M.G., Zhang Y., Pentel P.R. Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats. J Pharmacol Exp Ther 2008, 325(3):985-993.
25. Icardi G., Orsi A., Ceravolo A., Ansaldi F. Current evidence on intradermal influenza vaccines administered by Soluvia (TM) licensed micro injection system. Hum Vaccine Immunother 2012, 8(1):67-75.
26. Laurent P.E., Bonnet S., Alchas P., Regolini P., Mikszta J.A., Pettis R., et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007, 25(52):8833-8842.
27. Ansaldi F., de Florentiis D., Durando P., Icardi G. Fluzone((R)) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev Vaccines 2012, 11(1):17-25.
28. Prausnitz M.R., Mikszta J.A., Cormier M., Andrianov A.K. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009, 333:369-393.
29. Frech S.A., Dupont H.L., Bourgeois A.L., McKenzie R., Belkind-Gerson J., Figueroa J.F., et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008, 371(9629):2019-2025.
30. Pravetoni M., Keyler D.E., Pidaparthi R.R., Carroll F.I., Runyon S.P., Murtaugh M.P., et al. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol 2012, 83(4):543-550.
31. Keyler D.E., Roiko S.A., Earley C.A., Murtaugh M.P., Pentel P.R. Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 2008, 8(11):1589-1594.
32. de Villiers S.H., Lindblom N., Kalayanov G., Gordon S., Baraznenok I., Malmerfelt A., et al. Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure. Vaccine 2010, 28(10):2161-2168.